Ecallantide - Plasma kallikrein inhibitor, treatment of hereditary angioedema

被引：0

作者：

Revill, P. ^{[1
]}

Mealy, N. ^{[1
]}

机构：

[1] Prous Sci, Barcelona 08080, Spain

来源：

DRUGS OF THE FUTURE | 2007年 / 32卷 / 07期

关键词：

DX-88; EPI-KAL2;

D O I：

10.1358/dof.2007.032.07.1119724

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

C1 esterase inhibitor (C1-INH) activity is reduced in the blood of patients with hereditary angioedema (HAE) and is depleted in patients undergoing cardiopulmonary bypass surgery (CPB). The effect of this insufficiency is activation of the complement system, leading to inflammatory responses, and activation of the kallikrein-kinin system, leading to the swelling and pain associated with acute HAE attacks. Depleted C1-INH and elevated kallikrein are also believed to lie behind the inflammatory injuries and high blood loss associated with CPB surgery. Ecallantide is a recombinant protein inhibitor of kallikrein that is under development for the treatment of acute HAE attacks and to reduce blood loss in patients undergoing CPB surgery.

引用

页码：590 / 594

页数：5

共 50 条

[1] ECALLANTIDE: A PLASMA KALLIKREIN INHIBITOR FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA
Stolz, L. E.
Horn, P. T.
[J]. DRUGS OF TODAY, 2010, 46 (08) : 547 - 555
[2] Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor
Schneider, Lynda
Lumry, William
Vegh, Arthur
Williams, Anthony H.
Schmalbach, Tess
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (02) : 416 - 422
[3] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Lehmann, Andreas
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1187 - 1199
[4] Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
Aygoeren-Puersuen, E.
Bygum, A.
Grivcheva-Panovska, V.
Magerl, M.
Graff, J.
Steiner, U. C.
Fain, O.
Huissoon, A.
Kinaciyan, T.
Farkas, H.
Lleonart, R.
Longhurst, H. J.
Rae, W.
Triggiani, M.
Aberer, W.
Cancian, M.
Zanichelli, A.
Smith, W. B.
Baeza, M. L.
Du-Thanh, A.
Gompels, M.
Gonzalez-Quevedo, T.
Greve, J.
Guilarte, M.
Katelaris, C.
Dobo, S.
Cornpropst, M.
Clemons, D.
Fang, L.
Collis, P.
Sheridan, W.
Maurer, M.
Cicardi, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04): : 352 - 362
[5] Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema
Hwang, Jacqueline R.
Hwang, Gloria
Johri, Ansh
Craig, Timothy
[J]. IMMUNOTHERAPY, 2019, 11 (17) : 1439 - 1444
[6] ACUTE ATTACKS OF ACQUIRED ANGIOEDEMA RESPONDING TO KALLIKREIN INHIBITOR (ECALLANTIDE)
Vernon, N.
Ghaffari, G.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A90 - A90
[7] TREATMENT OF ABDOMINAL ATTACKS OF HEREDITARY ANGIOEDEMA WITH ECALLANTIDE
Sheffer, A. L.
Lembo, A. J.
Stolz, L. E.
Stevens, C.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A124 - A124
[8] Ecallantide is a novel treatment for attacks of hereditary angioedema due to Cl inhibitor deficiency
Farkas, Henriette
Varga, Lilian
[J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2011, 4 : 61 - 68
[9] Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema
Cicardi, Marco
Levy, Robyn J.
McNeil, Donald L.
Li, H. Henry
Sheffer, Albert L.
Campion, Marilyn
Horn, Patrick T.
Pullman, William E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (06): : 523 - 531
[10] Ecallantide In Treatment Of Type III Hereditary Angioedema
Nanda, Anil
Wasan, Anita N.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB38 - AB38

← 1 2 3 4 5 →